An Investigator-initiated Linked Study to OCEANIC-AF
ConditionAtrial Fibrillation
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorEast and North Hertfordshire NHS Trust
About this trial
Impaired endogenous fibrinolysis is a recently recognised risk factor for thrombotic events in patients with cardiovascular disease. Enhancing endogenous fibrinolysis in such individuals represents a way of reducing thrombosis risk. However, the optimal pharmacotherapy to enhance fibrinolysis is unclear.
The aim of this study is to assess the effect of asundexian on endogenous fibrinolysis and compare this to apixaban. If asundexian can enhance endogenous fibrinolysis, this could be used as targeted treatment for patients who despite optimal antithrombotic therapy, demonstrate impaired endogenous fibrinolysis.
Eligibility criteria
Qualifiers
Patients aged 18 years or over
Patients enrolled in OCEANIC-AF study
Free from the
Disqualifiers
The patient is willing and able to understand the Patient Information Sheet and provide written informed consent
The patient agrees to comply with the drawing of blood samples for the assessments.
Inability to provide valid informed consent
Patients aged < 18 years of age
Trial design
Treatments tested in this trial
- Thrombotic assessment
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
East and North Hertfordshire NHS Trust
Lead sponsor
University of Hertfordshire
Sponsor institution
Liverpool Heart and Chest Hospital NHS Foundation Trust
Collaborator
Source ClinicalTrials.gov